Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25169531 | 1.00 | ECE1 (0.50) | ECE1MEN1KMT2ANOD1ITGB2 | |
| SCHEMBL21724473 | 1.00 | ECE1 (0.50) | ECE1MEN1KMT2ANOD1ITGB2 | |
| SCHEMBL31036091 | 0.89 | NOD1 (0.55) | ECE1MEN1KMT2ANOD1ALDH1A1 | |
| SCHEMBL9664751 | 0.88 | NOD1 (0.62) | ECE1MEN1KMT2ANOD1ITGB3 | |
| SCHEMBL5273108 | 0.88 | NOD1 (0.62) | ECE1MEN1KMT2ANOD1ITGB3 | |
| SCHEMBL21724437 | 0.86 | NOD1 (0.65) | MEN1KMT2ANOD1ITGB3ITGA2B | |
| SCHEMBL21724210 | 0.86 | NOD1 (0.65) | MEN1KMT2ANOD1ITGB3ITGA2B | |
| SCHEMBL7702846 | 0.86 | NOD1 (0.65) | MEN1KMT2ANOD1ITGB3ITGA2B | |
| SCHEMBL6536277 | 0.86 | NOD1 (0.65) | MEN1KMT2ANOD1ITGB3ITGA2B | |
| SCHEMBL25175260 | 0.86 | NOD1 (0.65) | MEN1KMT2ANOD1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | ECE1 2497/4885MEN1 2346/4885KMT2A 3520/4885 |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | ECE1 3955/4885MEN1 2101/4885KMT2A 544/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | ECE1 2497/4885MEN1 2346/4885KMT2A 3520/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | ECE1 2497/4885MEN1 2346/4885KMT2A 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.